Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
An article reviews the use of glucagon-like peptide-' (GLP-1) receptor agonists for treatment of patients with type 2 diabetes mellitus associated with high cardiovascular risk, chronic heart failure with low left ventricular ejection fraction and diabetic nephropathy. The authors discuss the mechanisms of action of GLP-' receptor agonists, their main advantages (significant hypoglycemic effect, organoprotection and improved cardiovascular and renal outcomes) and dose-dependent side effects.